Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.
Bookmark and Share

ESMO 2016

7 - 11 Oct 2016
Bella Center, Copenhagen, Denmark
What does the Association of European Cancer Leagues (ECL) do?
Dr Wendy Yared - Director, Association of European Cancer Leagues (ECL)
What does the Association of European Cancer Leagues (ECL) do? ( Dr Wendy Yared - Director, Association of European Cancer Leagues (ECL) )
26 Oct 2016
Coming of age for CDK 4/6 inhibitors: Welcome and interactive session
Dr Giuesppe Curigliano - European Institute of Oncology, Milan, Italy
Coming of age for CDK 4/6 inhibitors: Welcome and interactive session ( Dr Giuesppe Curigliano - European Institute of Oncology, Milan, Italy )
26 Oct 2016
What are CDKs?
Dr Ghadeer Shubassi - FIRC Institute of Molecular Oncology (IFOM), Milan, Italy
What are CDKs? ( Dr Ghadeer Shubassi - FIRC Institute of Molecular Oncology (IFOM), Milan, Italy )
26 Oct 2016
CDK clinical trial results, benefit, side effects and costs
Dr Pierfranco Conte - Instituto Oncologico Veneto, Padua, Italy
CDK clinical trial results, benefit, side effects and costs ( Dr Pierfranco Conte - Instituto Oncologico Veneto, Padua, Italy )
26 Oct 2016
Extending indication of CDK 4/6 inhibitors in the adjuvant and neoadjuvant setti...
Dr Sara Hurvitz - UCLA Medical Center, Santa Monica, USA
Extending indication of CDK 4/6 inhibitors in the adjuvant and neoadjuvant setting ( Dr Sara Hurvitz - UCLA Medical Center, Santa Monica, USA )
26 Oct 2016
Current indications for CDK 4/6 inhibitors (plus antiestrogen), biomarkers
Dr Sibylle Loibl - German Breast Cancer Group
Current indications for CDK 4/6 inhibitors (plus antiestrogen), biomarkers ( Dr Sibylle Loibl - German Breast Cancer Group )
26 Oct 2016
Coming of age for CDK 4/6 inhibitors: Interactive session and close
Dr Giuesppe Curigliano - European Institute of Oncology, Milan, Italy
Coming of age for CDK 4/6 inhibitors: Interactive session and close ( Dr Giuesppe Curigliano - European Institute of Oncology, Milan, Italy )
26 Oct 2016
Biomarkers of sensitivity and resistance
Dr Joan Seoane - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
Biomarkers of sensitivity and resistance ( Dr Joan Seoane - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )
26 Oct 2016
Editor's ESMO 2016 roundup
Prof Gordon McVie - Editor in Chief, ecancer
Editor's ESMO 2016 roundup ( Prof Gordon McVie - Editor in Chief, ecancer )
24 Oct 2016
Abiraterone in patients with recurrent epithelial ovarian cancer
Dr Susanna Banerjee - The Royal Marsden, London, UK
Abiraterone in patients with recurrent epithelial ovarian cancer ( Dr Susanna Banerjee - The Royal Marsden, London, UK )
24 Oct 2016
Fatigue in men with castration resistant prostate cancer treated with enzalutami...
Dr Simon Chowdhury - Guy's Hospital, London, UK
Fatigue in men with castration resistant prostate cancer treated with enzalutamide ( Dr Simon Chowdhury -  Guy's Hospital, London, UK )
21 Oct 2016
PDL-1 assay concordance
Dr Jill Walker - AstraZeneca, UK
PDL-1 assay concordance ( Dr Jill Walker - AstraZeneca, UK )
20 Oct 2016
CDK4/6 inhibition: PALOMA2 versus MONALEESA2
Dr Michael Gnant - Medizinischen Universität Wien, Vienna, Austria
CDK4/6 inhibition: PALOMA2 versus MONALEESA2 ( Dr Michael Gnant - Medizinischen Universität Wien, Vienna, Austria )
17 Oct 2016
First evidence of significant clinical activity of PD1 inhibition in metastatic ...
Dr Julie Graff - Knight Cancer Institute, Oregon Health & Science University, Po...
First evidence of significant clinical activity of PD1 inhibition in metastatic prostate cancer ( Dr Julie Graff - Knight Cancer Institute, Oregon Health & Science University, Portland, USA )
17 Oct 2016
CDK4/6 inhibitors for metastatic breast cancer
Dr Giuseppe Curigliano - European Institute of Oncology, Milan, Italy
CDK4/6 inhibitors for metastatic breast cancer ( Dr Giuseppe Curigliano - European Institute of Oncology, Milan, Italy )
14 Oct 2016
TRAIL induced apoptosis for cancer stem cells
Prof Waleed Arafat - Alexandria Faculty of Medicine, Alexandria, Egypt
TRAIL induced apoptosis for cancer stem cells ( Prof Waleed Arafat - Alexandria Faculty of Medicine, Alexandria, Egypt )
12 Oct 2016
Carcinoid syndrome
Dr Rachel Riechelmann - Instituto do Câncer do Estado de São Paulo, São Paulo, B...
Carcinoid syndrome ( Dr Rachel Riechelmann - Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil )
12 Oct 2016
Who should receive combination therapy for ER positive breast cancer?
Dr Michael Gnant - Medizinischen Universität Wien, Vienna, Austria
Who should receive combination therapy for ER positive breast cancer? ( Dr Michael Gnant - Medizinischen Universität Wien, Vienna, Austria )
12 Oct 2016
Positive lessons of negative trials
Dr Bishal Gyawali - Nagoya University, Nagoya, Japan
Positive lessons of negative trials ( Dr Bishal Gyawali - Nagoya University, Nagoya, Japan )
12 Oct 2016
Drug repurposing of propranolol
Dr Pan Pantziarka - Anticancer Fund, UK
Drug repurposing of propranolol ( Dr Pan Pantziarka - Anticancer Fund, UK )
12 Oct 2016
ESMO 2016 conference highlights
Dr Bishal Gyawali - Nagoya University, Nagoya, Japan
ESMO 2016 conference highlights ( Dr Bishal Gyawali - Nagoya University, Nagoya, Japan )
12 Oct 2016
Risk of serious and fatal adverse events with sorafenib use in patients with sol...
Dr Bishal Gyawali - Nagoya University, Nagoya, Japan
Risk of serious and fatal adverse events with sorafenib use in patients with solid cancers ( Dr Bishal Gyawali - Nagoya University, Nagoya, Japan )
12 Oct 2016
Combination of MEDI0680, an anti-PD-1 antibody, with durvalumab, an anti-PD-L1 a...
Dr Omid Hamid - The Angeles Clinic, California, USA
Combination of MEDI0680, an anti-PD-1 antibody, with durvalumab, an anti-PD-L1 antibody: ( Dr Omid Hamid - The Angeles Clinic, California, USA )
12 Oct 2016
LUME study of nintedanib finds improved PFS, but no overall survival boost
Prof Eric Van Cutsem - University of Leuven, Leuven, Belgium
LUME study of nintedanib finds improved PFS, but no overall survival boost ( Prof Eric Van Cutsem - University of Leuven, Leuven, Belgium )
12 Oct 2016
ESMO 2016 prostate cancer highlights
Dr Eleni Efstathiou, Prof Karim Fizazi, Dr Chris Parker
ESMO 2016 prostate cancer highlights ( Dr Eleni Efstathiou, Prof Karim Fizazi, Dr Chris Parker )
10 Oct 2016
Left versus right sided GI tumour response in the CRYSTAL trial
Prof Eric Van Cutsem - University of Leuven, Leuven, Belgium
Left versus right sided GI tumour response in the CRYSTAL trial ( Prof Eric Van Cutsem - University of Leuven, Leuven, Belgium )
10 Oct 2016
Looking for new pathways in colorectal cancer
Prof Nils Brünner - Copenhagen University, Copenhagen, Denmark
Looking for new pathways in colorectal cancer ( Prof Nils Brünner - Copenhagen University, Copenhagen, Denmark )
10 Oct 2016
Caring for lung cancer patients
Dr Mark Doherty - Princess Margaret Hospital, Toronto, Canada
Caring for lung cancer patients ( Dr Mark Doherty - Princess Margaret Hospital, Toronto, Canada )
10 Oct 2016
Oncolytic virotherapy using coxsackie virus
Dr Hardev Pandha - University of Surrey, Guildford, UK
Oncolytic virotherapy using coxsackie virus ( Dr Hardev Pandha - University of Surrey, Guildford, UK )
10 Oct 2016
Results of the Activ8 trial of novel immunotherapy motolimod
Dr Ezra Cohen - UC San Diego, San Diego, USA
Results of the Activ8 trial of novel immunotherapy motolimod ( Dr Ezra Cohen - UC San Diego, San Diego, USA )
10 Oct 2016
Lurbinectedin in PARP resistant breast cancer
Dr Cristina Cruz - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
Lurbinectedin in PARP resistant breast cancer ( Dr Cristina Cruz - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )
10 Oct 2016
Monitoring patterns of care in mCRPC patients with the help of the Cancer Regist...
Dr Simon Chowdhury - Guy's Hospital, London, UK
Monitoring patterns of care in mCRPC patients with the help of the Cancer Registry ( Dr Simon Chowdhury - Guy's Hospital, London, UK )
10 Oct 2016
Lurbinectedin in BRCA 1/2 breast cancer
Dr Judith Balmaña - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
Lurbinectedin in BRCA 1/2 breast cancer ( Dr Judith Balmaña - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )
10 Oct 2016
Olaparib and paclitaxel for 2nd line gastric cancer therapy
Dr Yung-Jue Bang - Seoul National University, Seoul, South Korea
Olaparib and paclitaxel for 2nd line gastric cancer therapy ( Dr Yung-Jue Bang - Seoul National University, Seoul, South Korea )
10 Oct 2016
Innovative uses of kinase inhibitors in cancer
Dr Jordi Rodón - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
Innovative uses of kinase inhibitors in cancer ( Dr Jordi Rodón - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )
10 Oct 2016
Comment: Ipilimumab in high risk stage III melanoma
Dr Evandro De Azambuja - ‎Jules Bordet Institute, Brussels, Belgium
Comment: Ipilimumab in high risk stage III melanoma ( Dr Evandro De Azambuja - ‎Jules Bordet Institute, Brussels, Belgium )
10 Oct 2016
Comment: Niraparib for ovarian cancer
Dr Evandro De Azambuja - ‎Jules Bordet Institute, Brussels, Belgium
Comment: Niraparib for ovarian cancer ( Dr Evandro De Azambuja - ‎Jules Bordet Institute, Brussels, Belgium )
10 Oct 2016
Comment: Ribociclib for breast cancer
Dr Evandro De Azambuja - ‎Jules Bordet Institute, Brussels, Belgium
Comment: Ribociclib for breast cancer ( Dr Evandro De Azambuja - ‎Jules Bordet Institute, Brussels, Belgium )
10 Oct 2016
Treating CNS metastases from breast cancer with a peptide/paclitaxel conjugate
Prof Shou-Ching Tang - Augusta University Cancer Center, Augusta USA
Treating CNS metastases from breast cancer with a peptide/paclitaxel conjugate ( Prof Shou-Ching Tang - Augusta University Cancer Center, Augusta USA )
10 Oct 2016
Highlights of ESMO 2016
Dr Andrés Cervantes - ESMO 2016 Scientific Chair
Highlights of ESMO 2016 ( Dr Andrés Cervantes - ESMO 2016 Scientific Chair )
10 Oct 2016
Adjuvant sunitinib for renal cell carcinoma
Dr Alain Ravaud - Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
Adjuvant sunitinib for renal cell carcinoma ( Dr Alain Ravaud - Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France )
10 Oct 2016
Longer disease-free survival in phase III trial of sunitinib as adjuvant treatme...
Dr Alain Ravaud - Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
Longer disease-free survival in phase III trial of sunitinib as adjuvant treatment for kidney cancer ( Dr Alain Ravaud - Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France )
10 Oct 2016
Custirsen shows no survival benefit in metastatic prostate cancer
Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France
Custirsen shows no survival benefit in metastatic prostate cancer ( Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France )
10 Oct 2016
Benefits of adjuvant chemo for soft tissue sarcoma patients
Dr Alessandro Gronchi - National Cancer Institute, Milan, Italy
Benefits of adjuvant chemo for soft tissue sarcoma patients ( Dr Alessandro Gronchi - National Cancer Institute, Milan, Italy )
10 Oct 2016
Significant survival gains for neoadjuvant chemotherapy for high risk soft tissu...
Dr Alessandro Gronchi - National Cancer Institute, Milan, Italy
Significant survival gains for neoadjuvant chemotherapy for high risk soft tissue sarcoma ( Dr Alessandro Gronchi - National Cancer Institute, Milan, Italy )
10 Oct 2016
Cabozantinib over sunitinib for metastatic renal cell carcinoma
Dr Toni Choueiri - Dana Farber Cancer Institute, Boston, USA
Cabozantinib over sunitinib for metastatic renal cell carcinoma ( Dr Toni Choueiri - Dana Farber Cancer Institute, Boston, USA )
10 Oct 2016
Promising results in metastatic bladder cancer using immunotherapy
Dr Matthew Galsky - Mount Sinai, New York, USA
Promising results in metastatic bladder cancer using immunotherapy ( Dr Matthew Galsky - Mount Sinai, New York, USA )
10 Oct 2016
Negative trial results of custirsen for metastatic prostate cancer
Prof Karim Fizazi - Cancer Medicine at the Institut Gustave Roussy, Villejuif, F...
Negative trial results of custirsen for metastatic prostate cancer ( Prof Karim Fizazi - Cancer Medicine at the Institut Gustave Roussy, Villejuif, France )
10 Oct 2016
Cabozantinib improves PFS in metastatic renal cell carcinoma
Dr Toni Choueiri - Dana Farber Cancer Institute, Boston, USA
Cabozantinib improves PFS in metastatic renal cell carcinoma ( Dr Toni Choueiri - Dana Farber Cancer Institute, Boston, USA )
10 Oct 2016
ESMO 2016: Expert discussion on prostate cancer: Treatment safety and predictive...
Prof Bertrand Tombal and Dr Mark Beresford
ESMO 2016: Expert discussion on prostate cancer: Treatment safety and predictive markers ( Prof Bertrand Tombal and Dr Mark Beresford )
9 Oct 2016
Advances for NSCLC in review
Dr Stefan Zimmermann - Hôpital Fribourgeois, Fribourg, Switzerland
Advances for NSCLC in review ( Dr Stefan Zimmermann - Hôpital Fribourgeois, Fribourg, Switzerland )
9 Oct 2016
Ceritinib following crizotinib relapse for ALK positive NSCLC
Dr Giorgio Scagliotti - University of Turin, Turin, Italy
Ceritinib following crizotinib relapse for ALK positive NSCLC ( Dr Giorgio Scagliotti - University of Turin, Turin, Italy )
9 Oct 2016
Atezolizumab v docetaxel for NSCLC: results from the OAK trial
Dr Fabrice Barlesi - Hôpital Nord, Marseille, France
Atezolizumab v docetaxel for NSCLC: results from the OAK trial ( Dr Fabrice Barlesi - Hôpital Nord, Marseille, France )
9 Oct 2016
Significant survival gains with atezolizumab for NSCLC
Dr Fabrice Barlesi - Hôpital Nord, Marseille, France
Significant survival gains with atezolizumab for NSCLC ( Dr Fabrice Barlesi - Hôpital Nord, Marseille, France )
9 Oct 2016
Pembrolizumab new option for firstline treatment of advanced lung cancer with hi...
Dr Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany
Pembrolizumab new option for firstline treatment of advanced lung cancer with high PDL-1 expression ( Dr Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany )
9 Oct 2016
Pembrolizumab plus chemo as firstline therapy for NSCLC
Dr Corey Langer - University of Pennsylvania, Philadelphia, USA
Pembrolizumab plus chemo as firstline therapy for NSCLC ( Dr Corey Langer - University of Pennsylvania, Philadelphia, USA )
9 Oct 2016
ASCEND-5: Ceritinib for ALK positive NSCLC previously treated with crizotinib
Dr Giorgio Scagliotti - University of Turin, Turin, Italy
ASCEND-5: Ceritinib for ALK positive NSCLC previously treated with crizotinib ( Dr Giorgio Scagliotti - University of Turin, Turin, Italy )
9 Oct 2016
Pembrolizumab 'should be first line treatment' for high PD1 expressing NSCLC pat...
Dr Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany
Pembrolizumab 'should be first line treatment' for high PD1 expressing NSCLC patients ( Dr Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany )
9 Oct 2016
Firstline pembrolizumab plus chemo improves NSCLC outcomes
Dr Corey Langer - University of Pennsylvania, Philadelphia, USA
Firstline pembrolizumab plus chemo improves NSCLC outcomes ( Dr Corey Langer - University of Pennsylvania, Philadelphia, USA )
9 Oct 2016
KRAS in the clinic and conference
Dr Ana Vivancos - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
KRAS in the clinic and conference ( Dr Ana Vivancos - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )
9 Oct 2016
A potential prognostic biomarker of chemoresistance in mCRC treated with FUFIRI ...
Dr Arndt Stahler - University of Munich, Munich, Germany
A potential prognostic biomarker of chemoresistance in mCRC treated with FUFIRI or mIrOx (FIRE1) ( Dr Arndt Stahler - University of Munich, Munich, Germany )
9 Oct 2016
Thousands of melanoma patients in Europe have no access to new drugs
Prof Lidija Kandolf Sekulovic - Military Medical Academy, Belgrade, Serbia
Thousands of melanoma patients in Europe have no access to new drugs ( Prof Lidija Kandolf Sekulovic - Military Medical Academy, Belgrade, Serbia )
9 Oct 2016
Phase I results of a novel FGFR inhibitor
Dr Markus Joerger - Kantonsspital St. Gallen, St. Gallen, Switzerland
Phase I results of a novel FGFR inhibitor ( Dr Markus Joerger - Kantonsspital St. Gallen, St. Gallen, Switzerland )
9 Oct 2016
Firstline pembrolizumab for metastatic urothelial cancer
Dr Arjun Balar - NYU Langone Medical Center, New York, USA
Firstline pembrolizumab for metastatic urothelial cancer ( Dr Arjun Balar - NYU Langone Medical Center, New York, USA )
9 Oct 2016
Adjuvant immunotherapy improves melanoma outcomes
Prof Alexander Eggermont - Institut Gustave Roussy, Villejuif, France
Adjuvant immunotherapy improves melanoma outcomes ( Prof Alexander Eggermont - Institut Gustave Roussy, Villejuif, France )
8 Oct 2016
Adjuvant cetuximab in the PETACC8 trial for stage III colon cancer
Prof Julien Taïeb - Georges Pompidou European Hospital, Paris, France
Adjuvant cetuximab in the PETACC8 trial for stage III colon cancer ( Prof Julien Taïeb - Georges Pompidou European Hospital, Paris, France )
8 Oct 2016
FALCON trial: fulvestrant vs. anastrozole for HR advanced breast cancer
Prof John Robertson - University of Nottingham, Nottingham, UK
FALCON trial: fulvestrant vs. anastrozole for HR advanced breast cancer ( Prof John Robertson - University of Nottingham, Nottingham, UK )
8 Oct 2016
Fulvestrant in FALCON trial improves PFS in advanced breast cancer
Dr Matthew Ellis - Washington University in St Louis, USA
Fulvestrant in FALCON trial improves PFS in advanced breast cancer ( Dr Matthew Ellis - Washington University in St Louis, USA )
8 Oct 2016
Dabrafenib shows higher response and lower toxicity in paediatric brain cancer t...
Dr Mark Kieran - Dana-Farber/Boston Children’s Cancer and Blood Disorders Center...
Dabrafenib shows higher response and lower toxicity in paediatric brain cancer trial ( Dr Mark Kieran - Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Boston, USA )
8 Oct 2016
Ribociclib improves progression-free survival in advanced breast cancer
Prof Gabriel Hortobagyi - University of Texas MD Anderson Cancer Center, Houston...
Ribociclib improves progression-free survival in advanced breast cancer ( Prof Gabriel Hortobagyi - University of Texas MD Anderson Cancer Center, Houston, US )
8 Oct 2016
Outcome of ovarian cancer patients was significantly improved with niraparib
Dr Mansoor Raza Mirza - Copenhagen University Hospital, Copenhagen, Denmark
Outcome of ovarian cancer patients was significantly improved with niraparib ( Dr Mansoor Raza Mirza - Copenhagen University Hospital, Copenhagen, Denmark )
8 Oct 2016
Niraparib significantly improves outcomes for ovarian cancer patients
Dr Mansoor Raza Mirza - Rigshospitalet, Copenhagen University Hospital, Denmark
Niraparib significantly improves outcomes for ovarian cancer patients ( Dr Mansoor Raza Mirza - Rigshospitalet, Copenhagen University Hospital, Denmark )
8 Oct 2016
Ipilimumab as adjuvant therapy improves OS in high risk melanoma
Prof Alexander Eggermont - Institut Gustave Roussy, Villejuif, France
Ipilimumab as adjuvant therapy improves OS in high risk melanoma ( Prof Alexander Eggermont - Institut Gustave Roussy, Villejuif, France )
8 Oct 2016
Ribociclib improves PFS for postmenopausal women with hormone receptor-positive ...
Dr Gabriel Hortobagyi - MD Anderson, Houston, USA
Ribociclib improves PFS for postmenopausal women with hormone receptor-positive breast cancer ( Dr Gabriel Hortobagyi - MD Anderson, Houston, USA )
8 Oct 2016